Genentech GO30140- Solid Tumors

What is the Purpose of this Study?

We are doing this study to learn what effects, good or bad, atezolizumab has on you and your cancer when combined with bevacizumab and to make sure it is safe.
What is the Condition Being Studied?
Hepatocellular Carcinoma

Who Can Participate in this Study?

Adults who:

- Have advanced or metastatic and/or unresectable hepatocellular carcinoma

Age Group
Adults
Participating Institutions

What is Involved?

If you choose to join this study, you will:

- Receive either atezolizumab or atezolizumab and bevacizumab every 3 weeks through a vein in your arm

-- Continue to receive the study drug as long as your doctor thinks it is safe

Study Details

Full Title
An Open-Label, Multicenter Phase Ib Study of the Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors
Principal Investigator

Contacts
Gastrointestinal Oncology DCI Clinical Research Team
Protocol Number
IRB:
PRO00072845

NCT:
NCT02715531
ClinicalTrials.gov
View on ClinicalTrials.gov